Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 293

Similar articles for PubMed (Select 20212248)

1.

Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma.

Moskowitz CH, Schöder H, Teruya-Feldstein J, Sima C, Iasonos A, Portlock CS, Straus D, Noy A, Palomba ML, O'Connor OA, Horwitz S, Weaver SA, Meikle JL, Filippa DA, Caravelli JF, Hamlin PA, Zelenetz AD.

J Clin Oncol. 2010 Apr 10;28(11):1896-903. doi: 10.1200/JCO.2009.26.5942. Epub 2010 Mar 8.

2.

Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET.

Halasz LM, Jacene HA, Catalano PJ, Van den Abbeele AD, Lacasce A, Mauch PM, Ng AK.

Int J Radiat Oncol Biol Phys. 2012 Aug 1;83(5):e647-54. doi: 10.1016/j.ijrobp.2012.01.060. Epub 2012 May 18.

PMID:
22607911
3.

Prognostic significance of interim ¹⁸F-FDG PET/CT after three or four cycles of R-CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma.

Yang DH, Min JJ, Song HC, Jeong YY, Chung WK, Bae SY, Ahn JS, Kim YK, Bom HS, Chung IJ, Kim HJ, Lee JJ.

Eur J Cancer. 2011 Jun;47(9):1312-8. doi: 10.1016/j.ejca.2010.12.027. Epub 2011 Feb 18.

PMID:
21334197
4.

Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: a phase II GELTAMO trial.

Pardal E, Coronado M, Martín A, Grande C, Marín-Niebla A, Panizo C, Bello JL, Conde E, Hernández MT, Arranz R, Bargay J, González-Barca E, Pérez-Ceballos E, Montes-Moreno S, Caballero MD.

Br J Haematol. 2014 Nov;167(3):327-36. doi: 10.1111/bjh.13036. Epub 2014 Jul 28.

PMID:
25066542
5.

The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma.

Dunleavy K, Little RF, Pittaluga S, Grant N, Wayne AS, Carrasquillo JA, Steinberg SM, Yarchoan R, Jaffe ES, Wilson WH.

Blood. 2010 Apr 15;115(15):3017-24. doi: 10.1182/blood-2009-11-253039. Epub 2010 Feb 3.

6.

The impact of R-VACOP-B and interim FDG-PET/CT on outcome in primary mediastinal large B cell lymphoma.

Avigdor A, Sirotkin T, Kedmi M, Ribakovsy E, Berkowicz M, Davidovitz Y, Kneller A, Merkel D, Volchek Y, Davidson T, Goshen E, Apter S, Shimoni A, Ben-Bassat I, Nagler A.

Ann Hematol. 2014 Aug;93(8):1297-304. doi: 10.1007/s00277-014-2043-y. Epub 2014 Mar 5.

PMID:
24595734
7.

18F-fluorodeoxyglucose positron emission tomography in the staging and prognosis of T cell lymphoma.

Casulo C, Schöder H, Feeney J, Lim R, Maragulia J, Zelenetz AD, Horwitz S.

Leuk Lymphoma. 2013 Oct;54(10):2163-7. doi: 10.3109/10428194.2013.767901. Epub 2013 Mar 4.

8.

Use of interim [18F]fluorodeoxyglucose-positron emission tomography is not justified in diffuse large B-cell lymphoma during first-line immunochemotherapy.

Cox MC, Ambrogi V, Lanni V, Cavalieri E, Pelliccia S, Scopinaro F, Monarca B, Marchetti P, Spiriti MA.

Leuk Lymphoma. 2012 Feb;53(2):263-9. doi: 10.3109/10428194.2011.614704. Epub 2011 Sep 23.

PMID:
21846184
9.

18F-FDG PET/CT for early response assessment in diffuse large B-cell lymphoma: poor predictive value of international harmonization project interpretation.

Cashen AF, Dehdashti F, Luo J, Homb A, Siegel BA, Bartlett NL.

J Nucl Med. 2011 Mar;52(3):386-92. doi: 10.2967/jnumed.110.082586. Epub 2011 Feb 14.

10.

Impact of [(18)F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d'Etudes des Lymphomes de l'Adulte and GOELAMS.

Dupuis J, Berriolo-Riedinger A, Julian A, Brice P, Tychyj-Pinel C, Tilly H, Mounier N, Gallamini A, Feugier P, Soubeyran P, Colombat P, Laurent G, Berenger N, Casasnovas RO, Vera P, Paone G, Xerri L, Salles G, Haioun C, Meignan M.

J Clin Oncol. 2012 Dec 10;30(35):4317-22. doi: 10.1200/JCO.2012.43.0934. Epub 2012 Oct 29.

11.

Predictive value of interim ¹⁸F-FDG-PET/CT for event-free survival in patients with diffuse large B-cell lymphoma homogenously treated in a phase II trial with six cycles of R-CHOP-14 plus pegfilgrastim as first-line treatment.

González-Barca E, Canales M, Cortés M, Vidal MJ, Salar A, Oriol A, Bargay J, Bello JL, Sánchez JJ, Tomás JF, Donato E, Ferrer S, Caballero D; GELTAMO (Grupo Español de Linfoma y Trasplante de Médula Ósea).

Nucl Med Commun. 2013 Oct;34(10):946-52. doi: 10.1097/MNM.0b013e328363c695.

PMID:
23880897
12.

Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP.

Pregno P, Chiappella A, Bellò M, Botto B, Ferrero S, Franceschetti S, Giunta F, Ladetto M, Limerutti G, Menga M, Nicolosi M, Priolo G, Puccini B, Rigacci L, Salvi F, Vaggelli L, Passera R, Bisi G, Vitolo U.

Blood. 2012 Mar 1;119(9):2066-73. doi: 10.1182/blood-2011-06-359943. Epub 2012 Jan 10.

13.

Positron emission tomography/computed tomography findings during therapy predict outcome in patients with diffuse large B-cell lymphoma treated with chemotherapy alone but not in those who receive consolidation radiation.

Dabaja BS, Hess K, Shihadeh F, Podoloff DA, Medeiros LJ, Mawlawi O, Arzu I, Oki Y, Hagemeister FB, Fayad LE, Reed VK, Kedir A, Wogan CF, Rodriguez A.

Int J Radiat Oncol Biol Phys. 2014 Jun 1;89(2):384-91. doi: 10.1016/j.ijrobp.2014.02.015. Epub 2014 Apr 7.

PMID:
24721592
14.

Role of [18F]-fluoro-2-deoxy-D-glucose positron emission tomography in early and late therapy assessment of patients with advanced Hodgkin lymphoma treated with bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine and prednisone.

Markova J, Kahraman D, Kobe C, Skopalova M, Mocikova H, Klaskova K, Dedeckova K, Eich HT, Böll B, Dietlein M, Kozak T.

Leuk Lymphoma. 2012 Jan;53(1):64-70. doi: 10.3109/10428194.2011.603444. Epub 2011 Aug 24.

PMID:
21740300
15.

Response assessment after an inductive CHOP or CHOP-like regimen with or without rituximab in 103 patients with diffuse large B-cell lymphoma: integrating 18fluorodeoxyglucose positron emission tomography to the International Workshop Criteria.

Dupuis J, Itti E, Rahmouni A, Hemery F, Gisselbrecht C, Lin C, Copie-Bergman C, Belhadj K, El Gnaoui T, Gaillard I, Kuhnowski F, Meignan M, Haioun C.

Ann Oncol. 2009 Mar;20(3):503-7. doi: 10.1093/annonc/mdn671. Epub 2008 Dec 11.

16.

The rate of reduction in the maximum standardized uptake value from the initial to the post-R-CHOP therapy in positron emission tomography scan predicts disease progression in diffuse large B cell lymphoma patients.

Ishii Y, Tomita N, Tateishi U, Ishiyama Y, Yamamoto E, Hattori Y, Hagihara M, Yamazaki E, Ishigatsubo Y.

Med Oncol. 2014 Mar;31(3):880. doi: 10.1007/s12032-014-0880-0. Epub 2014 Feb 7.

PMID:
24504845
17.

FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease.

Kostakoglu L, Goldsmith SJ, Leonard JP, Christos P, Furman RR, Atasever T, Chandramouly A, Verma S, Kothari P, Coleman M.

Cancer. 2006 Dec 1;107(11):2678-87.

18.

Predictive value of (18)F-FDG hybrid PET/CT for the clinical outcome in patients with non-Hodgkin's lymphoma prior to and after autologous stem cell transplantation.

Qiao W, Zhao J, Wang C, Wang T, Xing Y.

Hematology. 2010 Feb;15(1):21-7. doi: 10.1179/102453310X12583347009739.

PMID:
20132658
19.

Interim [18F]fluorodeoxyglucose positron emission tomography scan in diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy plus rituximab.

Safar V, Dupuis J, Itti E, Jardin F, Fruchart C, Bardet S, Véra P, Copie-Bergman C, Rahmouni A, Tilly H, Meignan M, Haioun C.

J Clin Oncol. 2012 Jan 10;30(2):184-90. doi: 10.1200/JCO.2011.38.2648. Epub 2011 Dec 12.

20.

Utility of the PET-CT in the evaluation of early response to treatment in the diffuse large B-cell lymphoma. Preliminary results.

Cortés Romera M, Gámez Cenzano C, Caresia Aróztegui AP, Martín-Comín J, González-Barca E, Ricart Brulles Y, Palacios Abufón A, Robles Barba J, Rodríguez-Bel L, Rossi Seoane S, Fernández de Sevilla A.

Rev Esp Med Nucl Imagen Mol. 2012 May-Jun;31(3):135-41. doi: 10.1016/j.remn.2011.05.011. Epub 2011 Sep 23. English, Spanish.

PMID:
21944191
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk